Gallic acid synergistically enhances the antibacterial activity of azithromycin in MRSA.
Pseudomonas aeruginosa
Azithromycin
Combination therapy
Gallic acid
MRSA
MSSA
Journal
International microbiology : the official journal of the Spanish Society for Microbiology
ISSN: 1618-1905
Titre abrégé: Int Microbiol
Pays: Switzerland
ID NLM: 9816585
Informations de publication
Date de publication:
30 Aug 2024
30 Aug 2024
Historique:
received:
07
07
2024
accepted:
07
08
2024
revised:
04
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
30
8
2024
Statut:
aheadofprint
Résumé
The rise of antibiotic resistance in existing pathogens has been identified as a major threat to global healthcare in the twenty-first century. This resistance has consequences such as increased cost and prolonged hospital stays, treatment failure, and ultimately increased risk of patient mortality. It is therefore imperative to develop strategies to combat drug resistance. Combined treatment of common antibiotics and natural compounds is one of the most effective methods against resistant bacterial infections. Gallic acid (GA) is a natural secondary metabolite abundantly found in plants and has significant medicinal effects in various aspects of health. In this research, the antibacterial effects of azithromycin (AZM) and GA alone and in combination with each other were investigated on planktonic and biofilm forms of methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), and Pseudomonas aeruginosa (P. aeruginosa). The results showed that the combination of AZM/GA had an additive effect against MSSA and P. aeruginosa and a synergistic effect against MRSA. In addition, combining these two agents significantly reduced the minimum biofilm inhibitory concentration (MBIC) of AZM and GA in the MRSA strain. Finally, the level of ROS generation in the effect of AZM plus GA was evaluated in the bacteria. Among the studied strains, ROS production was significantly increased in combination treatment compared to AZM alone in MRSA. The results show that the combination of AZM and GA has a significant effect against MRSA and can be considered as an effective treatment option.
Identifiants
pubmed: 39212836
doi: 10.1007/s10123-024-00579-7
pii: 10.1007/s10123-024-00579-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Abebe GM (2020) The role of bacterial biofilm in antibiotic resistance and food contamination. Int J Microbiol 2020(1):10. https://doi.org/10.1155/2020/1705814
doi: 10.1155/2020/1705814
Albutti A, Gul MS, Siddiqui MF et al (2021) Combating biofilm by targeting its formation and dispersal using gallic acid against single and multispecies bacteria causing dental plaque. Pathogens 10(11):1486. https://doi.org/10.3390/pathogens10111486
doi: 10.3390/pathogens10111486
pubmed: 34832641
pmcid: 8618234
Askari M, Khezri M, Zoghi G (2022) Introducing a novel combination therapy with macrolides for the treatment of chronic rhinosinusitis: a randomized controlled trial. Iran J Med Sci 47:533–540. https://doi.org/10.30476/IJMS.2021.91813.2303
doi: 10.30476/IJMS.2021.91813.2303
pubmed: 36380971
pmcid: 9652494
Badhani B, Sharma N, Kakkar R (2015) Gallic acid: a versatile antioxidant with promising therapeutic and industrial applications. RSC Adv 5:27540–27557. https://doi.org/10.1039/c5ra01911g
doi: 10.1039/c5ra01911g
Basri DF, Xian LW, Abdul Shukor NI, Latip J (2014) Bacteriostatic antimicrobial combination: antagonistic interaction between epsilon-viniferin and vancomycin against methicillin-resistant staphylococcus aureus. BioMed Res Int 2014(1):461756. https://doi.org/10.1155/2014/461756
doi: 10.1155/2014/461756
pubmed: 24783205
pmcid: 3982270
Borozan AB, Popescu S, Madosa E et al (2023) Comparative study on the antimicrobial activity of propolis, catechin, quercetin and gallic acidcatechin, quercetin and gallic acidcatechin. Not Bot Horti Agrobo 51(2):12826. https://doi.org/10.15835/nbha51212826
doi: 10.15835/nbha51212826
Choubey S, Goyal S, Varughese LR et al (2018) Probing gallic acid for its broad spectrum applications. Mini-Reviews Med Chem 18:1283–1293. https://doi.org/10.2174/1389557518666180330114010
doi: 10.2174/1389557518666180330114010
de Almeida Campos LA, de Oliveira Santos JV, Cavalcanti ID, Neto AF, Nogueira MC, Santos-Magalhães NS, Cavalcanti IM (2023) Natural products and combination therapy as strategies against bacterial biofilm. Stud Nat Prod Chem 1(77):163–86. https://doi.org/10.1016/B978-0-323-91294-5.00006-3
doi: 10.1016/B978-0-323-91294-5.00006-3
Dhingra S, Rahman NAA, Peile E et al (2020) Microbial resistance movements: an overview of global public health threats posed by antimicrobial resistance, and how best to counter. Front Public Heal 8:1–22. https://doi.org/10.3389/fpubh.2020.535668
doi: 10.3389/fpubh.2020.535668
Doern CD (2014) When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol 52:4124–4128. https://doi.org/10.1128/JCM.01121-14
doi: 10.1128/JCM.01121-14
pubmed: 24920779
pmcid: 4313275
Dutescu IA, Hillie SA (2021) Encouraging the development of new antibiotics: are financial incentives the right way forward? A systematic review and case study. Infect Drug Resist 14:415–434. https://doi.org/10.2147/IDR.S287792
doi: 10.2147/IDR.S287792
pubmed: 33574682
pmcid: 7872909
El-Metwally HAE, Elmoageny NHH, Arafa SAEF (2022) Evaluation of the in-vitro synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus isolates. Microbes Infect Dis 3:920–932. https://doi.org/10.21608/MID.2022.158151.1373
doi: 10.21608/MID.2022.158151.1373
Firth A, Prathapan P (2020) Azithromycin: the first broad-spectrum therapeutic. Eur J Med Chem 207:112739. https://doi.org/10.1016/j.ejmech.2020.112739
doi: 10.1016/j.ejmech.2020.112739
pubmed: 32871342
pmcid: 7434625
Gao L, Tang Zh, Li T, et al (2021) Combination of kaempferol and azithromycin attenuates Staphylococcus aureus-induced osteomyelitis via anti-biofilm effects and by inhibiting the phosphorylation of ERK1/2 and SAPK. Pathog Dis 79(8). https://doi.org/10.1093/femspd/ftab048
Gaudereto JJ, Neto LVP, Leite GC et al (2020) Comparison of methods for the detection of in vitro synergy in multidrug-resistant gram-negative bacteria. BMC Microbiol 20:1–7. https://doi.org/10.1186/s12866-020-01756-0
doi: 10.1186/s12866-020-01756-0
Heidary M, Ebrahimi Samangani A, Kargari A et al (2022) Mechanism of action, resistance, synergism, and clinical implications of azithromycin. J Clin Lab Anal 36:1–16. https://doi.org/10.1002/jcla.24427
doi: 10.1002/jcla.24427
Hossain MA, Park HC, Park SW et al (2020) Synergism of the combination of traditional antibiotics and novel phenolic compounds against escherichia coli. Pathogens 9:1–23. https://doi.org/10.3390/pathogens9100811
doi: 10.3390/pathogens9100811
Ito A, Ishida T, Tachibana H et al (2019) Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis. Sci Rep 9:3–10. https://doi.org/10.1038/s41598-019-54922-4
doi: 10.1038/s41598-019-54922-4
Jiamboonsri P, Eurtivong C, Wanwong S (2023) Assessing the potential of gallic acid and methyl gallate to enhance the efficacy of β-Lactam antibiotics against methicillin-resistant staphylococcus aureus by targeting β-Lactamase: In Silico and In Vitro studies. Antibiotics 12(11):1622. https://doi.org/10.3390/antibiotics12111622
doi: 10.3390/antibiotics12111622
pubmed: 37998824
pmcid: 10669207
Kahkeshani N, Farzaei F, Fotouhi M et al (2019) An update on the potential mechanism of gallic acid as an antibacterial and anticancer agent. Iran J Basic Med Sci 22:225–237. https://doi.org/10.22038/ijbms.2019.32806.7897
doi: 10.22038/ijbms.2019.32806.7897
pubmed: 31156781
pmcid: 6528712
Kang J, Li Q, Liu L, Jin W, Wang J, Sun Y (2018) The specific effect of gallic acid on Escherichia coli biofilm formation by regulating pgaABCD genes expression. Appl Microbiol Biotechnol 102:1837–1846
doi: 10.1007/s00253-017-8709-3
pubmed: 29327068
Keyvani-Ghamsari S, Rahimi M, Khorsandi Kh (2023) An update on the potential mechanism of gallic acid as an antibacterial and anticancer agent. Food Sci Nutr 11:5856–5872. https://doi.org/10.1002/fsn3.3615
doi: 10.1002/fsn3.3615
pubmed: 37823155
pmcid: 10563697
Khorsandi K, Keyvani-Ghamsari S, KhatibiShahidi F et al (2021) A mechanistic perspective on targeting bacterial drug resistance with nanoparticles. J Drug Target 29(9):941–959. https://doi.org/10.1080/1061186X.2021.1895818
doi: 10.1080/1061186X.2021.1895818
pubmed: 33703979
Kosuru RY, Aashique M, Fathima A et al (2018) Revealing the dual role of gallic acid in modulating ampicillin sensitivity of Pseudomonas aeruginosa biofilms. Future Microbiol 13:297–312. https://doi.org/10.2217/fmb-2017-0132
doi: 10.2217/fmb-2017-0132
pubmed: 29446642
Kryzhevskyi V, Strokous V, Lifshyts Y et al (2023) Case report: azithromycin-meropenem combination therapy as a low-cost approach to combat PDR gram-negative infections of war wounds in Ukraine. Front Med 10:1264492. https://doi.org/10.3389/fmed.2023.1264492
doi: 10.3389/fmed.2023.1264492
Kumar M, Rao M, Mathur T et al (2021) Azithromycin exhibits activity against Pseudomonas aeruginosa in chronic rat lung infection model. Front Microbiol 12:1–9. https://doi.org/10.3389/fmicb.2021.603151
doi: 10.3389/fmicb.2021.603151
Li D, Wang Y (2021) Safety of azithromycin in pediatric infectious diseases: a clinical systematic review and meta-analysis. Transl Pediatr 10:2594–2601. https://doi.org/10.21037/tp-21-444
doi: 10.21037/tp-21-444
pubmed: 34765483
pmcid: 8578745
Li H, Liu DH, Chen LL et al (2014) Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob Agents Chemother 58:511–517. https://doi.org/10.1128/AAC.02067-13
doi: 10.1128/AAC.02067-13
pubmed: 24189261
pmcid: 3910718
Li YT, Huang JR, Li LJ, Liu LS (2017) Synergistic activity of berberine with azithromycin against Pseudomonas aeruginosa Isolated from patients with cystic fibrosis of lung in vitro and in vivo. Cell Physiol Biochem 42:1657–1669. https://doi.org/10.1159/000479411
doi: 10.1159/000479411
pubmed: 28738346
Lima N, Oliveira-tintino CDM, Santos ES et al (2016) Antimicrobial and enhancement of the antibiotic activity by phenolic compounds: Gallic acid, caffeic acid and pyrogallol. Microbial pathogenesis 99:56–61. https://doi.org/10.1016/j.micpath.2016.08.004
doi: 10.1016/j.micpath.2016.08.004
pubmed: 27497894
Lu Z, Tadi DA, Fu J et al (2022) Global status of azithromycin and erythromycin resistance rates in Neisseria gonorrhoeae: a systematic review and meta-analysis. Yale J Biol Med 95:465–478
pubmed: 36568835
pmcid: 9765340
Mack I, Sharland M, Berkley JA et al (2020) Antimicrobial resistance following azithromycin mass drug administration: potential surveillance strategies to assess public health impact. Clin Infect Dis 70:1501–1508. https://doi.org/10.1093/cid/ciz893
doi: 10.1093/cid/ciz893
pubmed: 31633161
Mancuso G, Midiri A, Gerace E, Biondo C (2021) Bacterial antibiotic resistance: the most critical pathogens. Pathogens 10:1–14. https://doi.org/10.3390/Pathogens12010116
doi: 10.3390/Pathogens12010116
Matzneller P, Krasniqi S, Kinzig M et al (2013) Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrob Agents Chemother 57:1736–1742. https://doi.org/10.1128/AAC.02011-12
doi: 10.1128/AAC.02011-12
pubmed: 23357769
pmcid: 3623349
Qayyum S, Oves M, Khan AU (2017) Obliteration of bacterial growth and biofilm through ROS generation by facilely synthesized green silver nanoparticles. PLoS ONE 12(8):e0181363. https://doi.org/10.1371/journal.pone.0181363
doi: 10.1371/journal.pone.0181363
pubmed: 28771501
pmcid: 5542591
Rajamanickam K, Yang J, Sakharkar MK (2019) Gallic acid potentiates the antimicrobial activity of tulathromycin against two key bovine respiratory disease (BRD) causing-pathogens. Front Pharmacol 9:1486. https://doi.org/10.3389/fphar.2018.01486
doi: 10.3389/fphar.2018.01486
pubmed: 30662404
pmcid: 6328469
Shao D, Li J, Li J et al (2015) Inhibition of gallic acid on the growth and biofilm formation of Escherichia coli and Streptococcus mutans. J Food Sci 80:M1299–M1305. https://doi.org/10.1111/1750-3841.12902
doi: 10.1111/1750-3841.12902
pubmed: 25974286
Tian QM, Wei SM, Su HR et al (2022) Synergism of the combination of traditional an_tibiotics and novel phenolic compounds against Escherichia. Microb Pathog 173:105824. https://doi.org/10.1016/j.micpath.2022.105824
doi: 10.1016/j.micpath.2022.105824
pubmed: 36243382
Wang Q, de Oliveira EF, Alborzi S, Bastarrachea LJ, Tikekar RV (2017) On mechanism behind UV-A light enhanced antibacterial activity of gallic acid and propyl gallate against Escherichia coli O157: H7. Sci Rep 7(1):8325. https://doi.org/10.1038/s41598-017-08449-1
doi: 10.1038/s41598-017-08449-1
pubmed: 28814799
pmcid: 5559599
Wang J, Li S, Meng J et al (2022a) Baicalin acts as an adjuvant to potentiate the activity of azithromycin against Staphylococcus saprophyticus biofilm: an in vitro, in vivo, and molecular study. Vet Res 53:83. https://doi.org/10.1186/s13567-022-01088-z
doi: 10.1186/s13567-022-01088-z
pubmed: 36224607
pmcid: 9558388
Wang N, Luo J, Deng F, Huang Y, Zhou H (2022b) Antibiotic combination therapy: a strategy to overcome bacterial resistance to aminoglycoside antibiotics. Front Pharmacol 13:839808. https://doi.org/10.3389/fphar.2022.839808
doi: 10.3389/fphar.2022.839808
pubmed: 35281905
pmcid: 8905495